内視鏡用止血剤の世界市場レポート2026-2032

QY Research > レポート一覧 > 医療機器と消耗材 > 内視鏡用止血剤の世界市場レポート2026-2032

英文タイトル： Global Hemostatic Agents in Endoscopy Market Outlook, In‑Depth Analysis & Forecast to 2032

レポートID：2092359
発表時期：2026-09-04
訪問回数：471
ページ数：102
レポート形式：PDF
レポート言語：英語、日本語
グラフ数：112
レポートカテゴリ：医療機器と消耗材

販売価格（消費税別）

個人版
詳細
マルチユーザー版
詳細
企業版
詳細

価格表記: USDを日本円(税抜)に換算，本日の銀行送金レート: 1USD=162.50円。
※米ドル表示価格+10％消費税。

英語版

日本語版

英語と日本語版

価格表記: USDを日本円(税抜)に換算，本日の銀行送金レート: 1USD=162.50円。
※米ドル表示価格+10％消費税。

お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合，注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。但し、日本語版が必要な場合は、受注後8～10営業日となります。お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

概要

本報告書は、内視鏡用止血剤の世界市場について、容量、生産量、収益、価格の概要を紹介します。2021年から2025年までの過去の市場収益/売上データ、2026年の予測データ、ならびに2032年までのCAGR（年平均成長率）予測を含む、世界市場動向の分析を提供します。本レポートは、メーカー、地域、製品種類、およびエンドユーザー産業の観点から、世界と主要地域の市場現状と将来性を研究したものです。世界と主要地域のトップメーカーを分析し、製品タイプおよびアプリケーション/エンドユーザー産業別に内視鏡用止血剤市場を分類しています。

内視鏡用止血剤の世界市場レポート2026-2032

主要市場統計

予測期間

2025年~2032年

2025年の評価

160

2026年の予測

181

2032年の予測

364

CAGR(2025~2032)年

12.4%

本レポートでは、世界の内視鏡用止血剤市場の主要参加企業として、企業概要、販売数量、収益、価格、粗利益率、製品ポートフォリオ、地理的位置、主要な事業展開を以下のパラメータに基づいて紹介します。
本レポートは内視鏡用止血剤の主要生産者を調査するとともに、主要地域や国の消費状況も提供します。内視鏡用止血剤の主要地域／国における将来の市場ポテンシャルを重点的に分析し、それに基づき、異なるセグメントおよびサブセグメントにおける市場の将来動向を予測しております。アメリカ、カナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、その他の国々について、各国データおよび市場価値分析を提供しております。
2021年から2032年までの期間について、タイプ別および用途別の売上高、収益、価格に基づくセグメントデータを分析します。

本研究に含まれる主な企業は以下の通りです：
Cook Medical
3-D Matrix
EndoClot Plus
Next Biomedical
BioCer Entwicklungs

タイプ別市場セグメント：
Peptide Hydrogels
Mineral Hemostatic Powder
Other

用途別市場セグメント：
ESD
EMR
Other

地域別の市場セグメント：
北米
アジア太平洋
欧州
中南米
中東・アフリカ

本レポートの詳細内容：
世界の内視鏡用止血剤市場の現状と将来展望を包括的に分析し、グローバル主要地域における開発動向の綿密な調査を通じて、企業様に包括的な市場分析を提示します。市場の全体像を把握するため、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいて内視鏡用止血剤市場を細分化しています。この分類と用途分析により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
一. 生産面では、2021年から2026年までの実績と2032年までの予測として、メーカー別、地域別（地域レベル、国レベル）の内視鏡用止血剤生産量、成長率、市場シェアを調査しています。
二. 消費面では、内視鏡用止血剤の売上高について、地域別（地域レベル・国レベル）、企業別、種類別、用途別に焦点を当てています。2021年から2026年まで、および2032年までの予測を対象とします。
三. 主要メーカーの内視鏡用止血剤売上高、収益、市場シェア、業界ランキングについて、2021年から2026年までのデータに焦点を当てています。世界の内視鏡用止血剤市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づく競争状況と市場ポジショニングの分析を行います。
四. 本内視鏡用止血剤レポートは、関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立案するのに役立つ洞察を提供することを目的としています。売上高、成長動向、生産技術、用途、エンドユーザー産業に関する市場規模の詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。
章節目次：
第1章：内視鏡用止血剤レポートの範囲、市場セグメント（タイプ別、用途別など）ごとの市場規模、将来の発展可能性などをまとめたエグゼクティブサマリーをご紹介いたします。これにより、市場の最新状況を包括的に把握し、短期・中期・長期（2021-2032年）にわたる発展の見通しを把握いただけます。
第2章：内視鏡用止血剤の世界および主要生産者（地域／国別）の生産量／アウトプットについて分析します。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています（2021年～2032年）
第3章：内視鏡用止血剤の現在の市場状況を提示し、2032年までの世界的な収益・販売・生産を予測するとともに、消費量の多い地域と新興市場の成長要因を特定します（2021年～2032年）
第4章：内視鏡用止血剤メーカーの競争状況、価格、売上高、収益、市場シェア、業界ランキング、最新の開発計画、合併・買収情報など詳細に分析します（2021年～2026年）
第5章：内視鏡用止血剤の下流市場機会を特定し、用途別販売量・収益・価格設定を評価するとともに新興ユースケースを明らかにし、地域別・用途別の主要顧客をプロファイリングします
第6章：内視鏡用止血剤のグローバル生産能力、稼働率、市場シェア（2021-2032年）をマッピングし、効率的拠点を特定するとともに規制や貿易政策の影響とボトルネックを解明します
第7章：北米における内視鏡用止血剤市場をアプリケーション別・国別売上高・収益で分析し、主要メーカーをプロファイリングしつつ成長要因と障壁を評価します
第8章：欧州における内視鏡用止血剤市場をアプリケーション別・メーカー別に地域別売上高・収益・市場分析を行い、成長要因と障壁を明示します
第9章：アジア太平洋地域の内視鏡用止血剤市場を用途別・地域/国別の売上高と収益で定量化し、主要メーカーをプロファイリングするとともに高成長潜在地域を明らかにします
第10章：中南米における内視鏡用止血剤市場を用途別・国別売上高と収益で測定し、主要メーカーをプロファイリングするとともに投資機会と課題を特定します
第11章：中東・アフリカ地域の内視鏡用止血剤市場を用途別・国別に評価し、主要メーカーをプロファイリングするとともに投資見通しと市場障壁を概説します
第12章：内視鏡用止血剤の主要メーカーの概要を提供し、製品説明、売上高、収益、価格、粗利益率、最近の事業拡大などの情報を整理するとともに、SWOT分析および戦略動向分析を行います
第13章：内視鏡用止血剤のサプライチェーンを分析し、上流の原材料・供給業者、製造拠点と技術、コスト要因を明らかにします
第14章：内視鏡用止血剤の市場動向、最新動向、推進要因と制約要因、業界内のメーカーが直面する課題とリスク、関連する業界政策の分析を紹介します
第15章：レポートの要点と結論
第16章：付録

Description

The global Hemostatic Agents in Endoscopy market is projected to grow from US$ 160 million in 2025 to US$ 364 million by 2032, at a CAGR of 12.4% (2026-2032), driven by critical product segments and diverse end‑use applications.

Hemostatic Agents in Endoscopy refers to topical or locally delivered hemostatic materials designed for gastrointestinal endoscopic procedures to control active bleeding, support post-procedural hemostasis, and provide protective coverage over mucosal defects. These products are delivered through an endoscope in the form of powders, hydrogels, sprays, adhesive barriers, or other absorbable formulations and achieve hemostasis through mechanisms such as rapid fluid absorption, concentration of platelets and coagulation factors, formation of a mechanical barrier, moisture-activated adhesion, or self-assembling hydrogel formation. Key product characteristics include speed of initial hemostasis, coverage of broad or irregular bleeding surfaces, adhesion and persistence in wet gastrointestinal environments, catheter deliverability, visualization during treatment, biocompatibility, rebleeding performance, and compatibility with standard endoscopic workflows. Hemostatic Agents in Endoscopy are used in gastrointestinal bleeding management and therapeutic procedures including endoscopic mucosal resection, endoscopic submucosal dissection, polypectomy, tumor-related bleeding, ulcer bleeding, and other situations requiring rapid topical control of bleeding. This research focuses on finished endoscopically delivered hemostatic agents and evaluates the market by product technology, clinical application, regional demand, industry chain, sales channels, and competitive structure.

Key Findings
Mineral Hemostatic Powder accounted for approximately 53.8% of global Hemostatic Agents in Endoscopy revenue in 2025
ESD represented approximately 61.9% of global Hemostatic Agents in Endoscopy revenue by application in 2025
The five leading manufacturers collectively accounted for approximately 95.9% of global market revenue in 2025
North America represented approximately 36.6% of global revenue in 2025 while Asia-Pacific showed a comparable market scale
Non-contact powders and hydrogels are becoming increasingly important in complex gastrointestinal bleeding management
Market Trends
The Hemostatic Agents in Endoscopy market is moving toward non-contact, broad-coverage and easier-to-deploy technologies that can rapidly control diffuse or technically difficult bleeding without requiring precise mechanical targeting. Mineral and polysaccharide powders continue to serve large bleeding surfaces efficiently, while adhesive polymer systems and self-assembling peptide hydrogels are expanding the range of available mechanisms and clinical use scenarios. Product development is increasingly focused on stronger tissue adhesion, longer residence time, resistance to wash-off in wet gastrointestinal environments, reduced catheter blockage, improved spray or gel delivery, and preservation of visualization during treatment. Another important trend is the growing use of topical hemostatic agents around EMR and ESD procedures, where large mucosal defects and multiple potential bleeding points create demand for solutions that provide broad wound coverage and may support management of immediate and delayed bleeding. As the market matures, differentiation is shifting from initial hemostasis alone toward rebleeding control, procedural efficiency, delivery reliability, clinical evidence, and integration with multimodal endoscopic treatment.

Market Dynamics
Drivers
Growth of the Hemostatic Agents in Endoscopy market is primarily driven by increasing volumes of therapeutic gastrointestinal endoscopy, broader use of EMR and ESD, and continued demand for minimally invasive management of gastrointestinal bleeding. Conventional clipping, thermal coagulation and injection techniques can be technically challenging in diffuse bleeding, large lesions, friable tumors or anatomically difficult locations, creating a clear role for topical agents capable of covering a wider treatment surface. Expansion of specialized gastroenterology centers, improvements in endoscopic equipment and physician training, and greater detection of gastrointestinal lesions further enlarge the addressable procedure base. The disposable nature of most delivery systems also supports recurring demand directly linked to procedure volumes.

Restraints
Market development is constrained by the relatively high procedure-level cost of specialized hemostatic agents compared with conventional endoscopic techniques, particularly in healthcare systems without dedicated reimbursement. Some products provide rapid initial hemostasis but may form temporary barriers that can detach or degrade, creating the possibility of rebleeding and requiring subsequent clipping, thermal treatment, angiographic intervention or surgery in high-risk cases. Technical limitations such as catheter blockage, uneven powder dispersion, reduced performance after premature contact with blood or moisture, and temporary obscuration of the endoscopic field can also affect physician adoption. Differences in regulatory approval, reimbursement and hospital purchasing policies further limit uniform market penetration.

Opportunities
Important opportunities are emerging from the expansion of complex EMR, ESD and other advanced therapeutic endoscopy procedures, particularly in markets where these techniques are still increasing in penetration. Products that combine rapid hemostasis with reliable adhesion, broad surface coverage, good visualization and longer persistence can address unmet needs associated with large resection beds and difficult-to-access bleeding sites. Development of transparent gels, improved absorbable powders, moisture-activated adhesive systems and more reliable delivery catheters can further broaden clinical utility. Geographic expansion through partnerships with established endoscopy companies and regional distributors also creates opportunities to improve access in developing healthcare markets where advanced gastrointestinal endoscopy capacity is expanding.

Challenges
The principal industry challenge is achieving consistent clinical effectiveness across different bleeding severities, lesion types, anatomical locations and operator techniques. A product that performs well in diffuse oozing may not be sufficient as definitive monotherapy for severe arterial bleeding, meaning that clinical positioning must often account for adjunctive, rescue or bridge use. Manufacturers also face the challenge of demonstrating reductions in rebleeding, repeat intervention and overall treatment cost through sufficiently robust clinical evidence. At the same time, they must maintain reliable powder propulsion or gel delivery, prevent catheter blockage, ensure biocompatibility and sterility, and meet different regulatory requirements across international markets. These factors raise development costs and lengthen commercialization cycles.

Industry Chain Analysis
The upstream segment of the Hemostatic Agents in Endoscopy industry includes functional hemostatic materials such as mineral absorbents, absorbable polysaccharides, synthetic polymers and self-assembling peptides, together with pharmaceutical-grade water, buffers, stabilizers, viscosity modifiers and other formulation inputs. Packaging and delivery components, including syringes, powder cartridges, applicators, endoscopic catheters, connectors and sterile barrier packaging, are also critical because product performance depends not only on the active material but on reliable delivery through the endoscope. Raw-material purity, particle-size distribution, polymer consistency, peptide purity, endotoxin control and sterilization compatibility directly influence clinical performance and manufacturing quality.

The midstream stage includes formulation, peptide or polymer processing, particle engineering, aseptic or powder filling, sterilization, packaging, catheter integration, quality inspection and final product release. Value creation is concentrated in proprietary material technology and the ability to translate that technology into predictable hemostasis, tissue adherence, catheter compatibility and clinical usability. Downstream customers consist mainly of hospitals, gastroenterology departments, ambulatory surgical centers and specialist endoscopy clinics. Large hospitals and healthcare groups commonly purchase through direct contracts, tenders or group purchasing organizations, while regional distributors remain important in geographically fragmented markets. Profitability therefore depends on formulation differentiation, manufacturing quality, regulatory approvals, clinical evidence, procedural convenience and access to endoscopy sales channels.

Segment Insights
By product technology, Mineral Hemostatic Powder represented approximately 53.8% of global Hemostatic Agents in Endoscopy revenue in 2025 and remained the largest segment, reflecting its established use for rapid non-contact coverage of active gastrointestinal bleeding. Peptide Hydrogels accounted for a smaller share but showed a structurally different value proposition based on transparent application, localized physical barrier formation and suitability for advanced therapeutic endoscopy. The remaining market includes polysaccharide-based powders and adhesive polymer systems, which compete through absorbability, moisture interaction, tissue adherence and delivery characteristics. The segment structure therefore reflects multiple complementary hemostatic mechanisms rather than a single standardized technology.

By application, ESD represented approximately 61.9% of global revenue in 2025, compared with approximately one-quarter for EMR, while other gastrointestinal bleeding applications accounted for the remainder. ESD has particularly strong demand for topical hemostatic technologies because the procedure creates large artificial ulcers and exposes multiple submucosal vessels, increasing the need for intraoperative bleeding control and broad post-resection coverage. Continued expansion of advanced resection procedures is therefore likely to increase the strategic importance of products optimized for prolonged procedures, large treatment areas and delayed-bleeding management.

Downstream Market Opportunities
The most attractive downstream opportunities for Hemostatic Agents in Endoscopy are concentrated in high-volume hospitals and specialist endoscopy centers performing advanced gastrointestinal interventions. These customers increasingly value products that can rapidly cover diffuse bleeding, reduce time spent targeting multiple individual bleeding points, maintain endoscopic visualization, and integrate easily with existing catheters and therapeutic workflows. Growth of EMR, ESD and complex polypectomy expands demand for products capable of treating large mucosal defects, while outpatient migration of selected endoscopic procedures creates additional opportunities for ready-to-use systems with simple preparation and predictable performance. Manufacturers that can demonstrate clinical efficiency, lower rebleeding risk, reliable delivery and favorable procedure-level economics are better positioned to increase downstream adoption.

Regional Insights
North America represented approximately 36.6% of global Hemostatic Agents in Endoscopy revenue in 2025 and remains an important commercial market due to developed gastrointestinal endoscopy infrastructure, high treatment expenditure and broad access to advanced endoscopic technologies. Europe also maintains a substantial market supported by established gastroenterology services and increasing use of therapeutic endoscopy. In these mature regions, adoption is influenced not only by initial hemostatic effectiveness but also by clinical evidence, reimbursement conditions, physician familiarity, product availability and total treatment economics.

Asia-Pacific represented a market scale close to North America in 2025 and is becoming increasingly important as therapeutic endoscopy capacity expands. East Asian markets have particularly strong experience with EMR and ESD, supporting demand for products suited to large resection beds and prolonged procedures, while China and other developing Asian markets continue to expand hospital endoscopy capacity and physician training. Latin America and the Middle East & Africa remain smaller markets but offer longer-term opportunities as advanced gastrointestinal endoscopy becomes more accessible, although reimbursement, regulatory approval and distribution coverage continue to create significant regional differences.

Competitive Landscape Analysis
The Hemostatic Agents in Endoscopy market is highly concentrated, with the five leading manufacturers accounting for approximately 95.9% of global revenue in 2025. Competition is differentiated by hemostatic mechanism and technology platform: established mineral powders compete through rapid non-contact coverage and broad clinical familiarity; self-assembling peptide hydrogels emphasize transparency, localized barrier formation and compatibility with advanced resection procedures; absorbable polysaccharide powders focus on fluid absorption and concentration of coagulation components; and adhesive polymer systems compete through moisture-activated tissue adherence. Leading participants such as Cook Medical, 3-D Matrix, EndoClot Plus, Next Biomedical and BioCer Entwicklungs therefore occupy different technology positions rather than offering completely interchangeable products. Competitive advantage increasingly depends on clinical evidence, rebleeding performance, catheter reliability, regulatory approvals, physician education, international distribution and the ability to demonstrate procedural value beyond initial bleeding control.

Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Hemostatic Agents in Endoscopy market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.

Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation
By Company
Cook Medical
3-D Matrix
EndoClot Plus
Next Biomedical
BioCer Entwicklungs

Segment by Type
Peptide Hydrogels
Mineral Hemostatic Powder
Other

Segment by Product
Self-assembling Type
Spray Type
Other

Segment by Biodegradability
Absorbable / Biodegradable Agents
Temporary Non-Absorptive Barrier Systems

Segment by Application
ESD
EMR
Other

Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA

Chapter Outline
Chapter 1: Defines the Hemostatic Agents in Endoscopy study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).

Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

Table of Contents

1 Study Coverage
1.1 Introduction to Hemostatic Agents in Endoscopy: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Hemostatic Agents in Endoscopy Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Peptide Hydrogels
1.2.3 Mineral Hemostatic Powder
1.2.4 Other
1.3 Market Segmentation by Product
1.3.1 Global Hemostatic Agents in Endoscopy Market Size by Product, 2021 vs 2025 vs 2032
1.3.2 Self-assembling Type
1.3.3 Spray Type
1.3.4 Other
1.4 Market Segmentation by Biodegradability
1.4.1 Global Hemostatic Agents in Endoscopy Market Size by Biodegradability, 2021 vs 2025 vs 2032
1.4.2 Absorbable / Biodegradable Agents
1.4.3 Temporary Non-Absorptive Barrier Systems
1.5 Market Segmentation by Application
1.5.1 Global Hemostatic Agents in Endoscopy Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 ESD
1.5.3 EMR
1.5.4 Other
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Hemostatic Agents in Endoscopy Revenue Estimates and Forecasts (2021-2032)
2.2 Global Hemostatic Agents in Endoscopy Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Hemostatic Agents in Endoscopy Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Hemostatic Agents in Endoscopy Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Peptide Hydrogels: Market Share by Key Players
3.3.2 Mineral Hemostatic Powder: Market Share by Key Players
3.3.3 Other: Market Share by Key Players
3.4 Global Hemostatic Agents in Endoscopy Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Hemostatic Agents in Endoscopy Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Hemostatic Agents in Endoscopy Market by Product
4.2.1 Global Revenue by Product (2021-2032)
4.2.2 Global Revenue-Based Market Share by Product (2021-2032)
4.3 Global Hemostatic Agents in Endoscopy Market by Biodegradability
4.3.1 Global Revenue by Biodegradability (2021-2032)
4.3.2 Global Revenue-Based Market Share by Biodegradability (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Hemostatic Agents in Endoscopy Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Hemostatic Agents in Endoscopy Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Hemostatic Agents in Endoscopy Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Hemostatic Agents in Endoscopy Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Hemostatic Agents in Endoscopy Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Hemostatic Agents in Endoscopy Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Hemostatic Agents in Endoscopy Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Hemostatic Agents in Endoscopy Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Hemostatic Agents in Endoscopy Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Hemostatic Agents in Endoscopy Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Hemostatic Agents in Endoscopy Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Cook Medical
11.1.1 Cook Medical Corporation Information
11.1.2 Cook Medical Business Overview
11.1.3 Cook Medical Hemostatic Agents in Endoscopy Product Features and Attributes
11.1.4 Cook Medical Hemostatic Agents in Endoscopy Revenue and Gross Margin (2021-2026)
11.1.5 Cook Medical Hemostatic Agents in Endoscopy Revenue by Product in 2025
11.1.6 Cook Medical Hemostatic Agents in Endoscopy Revenue by Application in 2025
11.1.7 Cook Medical Hemostatic Agents in Endoscopy Revenue by Geographic Area in 2025
11.1.8 Cook Medical Hemostatic Agents in Endoscopy SWOT Analysis
11.1.9 Cook Medical Recent Developments
11.2 3-D Matrix
11.2.1 3-D Matrix Corporation Information
11.2.2 3-D Matrix Business Overview
11.2.3 3-D Matrix Hemostatic Agents in Endoscopy Product Features and Attributes
11.2.4 3-D Matrix Hemostatic Agents in Endoscopy Revenue and Gross Margin (2021-2026)
11.2.5 3-D Matrix Hemostatic Agents in Endoscopy Revenue by Product in 2025
11.2.6 3-D Matrix Hemostatic Agents in Endoscopy Revenue by Application in 2025
11.2.7 3-D Matrix Hemostatic Agents in Endoscopy Revenue by Geographic Area in 2025
11.2.8 3-D Matrix Hemostatic Agents in Endoscopy SWOT Analysis
11.2.9 3-D Matrix Recent Developments
11.3 EndoClot Plus
11.3.1 EndoClot Plus Corporation Information
11.3.2 EndoClot Plus Business Overview
11.3.3 EndoClot Plus Hemostatic Agents in Endoscopy Product Features and Attributes
11.3.4 EndoClot Plus Hemostatic Agents in Endoscopy Revenue and Gross Margin (2021-2026)
11.3.5 EndoClot Plus Hemostatic Agents in Endoscopy Revenue by Product in 2025
11.3.6 EndoClot Plus Hemostatic Agents in Endoscopy Revenue by Application in 2025
11.3.7 EndoClot Plus Hemostatic Agents in Endoscopy Revenue by Geographic Area in 2025
11.3.8 EndoClot Plus Hemostatic Agents in Endoscopy SWOT Analysis
11.3.9 EndoClot Plus Recent Developments
11.4 Next Biomedical
11.4.1 Next Biomedical Corporation Information
11.4.2 Next Biomedical Business Overview
11.4.3 Next Biomedical Hemostatic Agents in Endoscopy Product Features and Attributes
11.4.4 Next Biomedical Hemostatic Agents in Endoscopy Revenue and Gross Margin (2021-2026)
11.4.5 Next Biomedical Hemostatic Agents in Endoscopy Revenue by Product in 2025
11.4.6 Next Biomedical Hemostatic Agents in Endoscopy Revenue by Application in 2025
11.4.7 Next Biomedical Hemostatic Agents in Endoscopy Revenue by Geographic Area in 2025
11.4.8 Next Biomedical Hemostatic Agents in Endoscopy SWOT Analysis
11.4.9 Next Biomedical Recent Developments
11.5 BioCer Entwicklungs
11.5.1 BioCer Entwicklungs Corporation Information
11.5.2 BioCer Entwicklungs Business Overview
11.5.3 BioCer Entwicklungs Hemostatic Agents in Endoscopy Product Features and Attributes
11.5.4 BioCer Entwicklungs Hemostatic Agents in Endoscopy Revenue and Gross Margin (2021-2026)
11.5.5 BioCer Entwicklungs Hemostatic Agents in Endoscopy Revenue by Product in 2025
11.5.6 BioCer Entwicklungs Hemostatic Agents in Endoscopy Revenue by Application in 2025
11.5.7 BioCer Entwicklungs Hemostatic Agents in Endoscopy Revenue by Geographic Area in 2025
11.5.8 BioCer Entwicklungs Hemostatic Agents in Endoscopy SWOT Analysis
11.5.9 BioCer Entwicklungs Recent Developments

12 Hemostatic Agents in Endoscopy Value Chain and Ecosystem Analysis
12.1 Hemostatic Agents in Endoscopy Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Hemostatic Agents in Endoscopy Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Hemostatic Agents in Endoscopy Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

Table of Figures

List of Tables
 Table 1. Global Hemostatic Agents in Endoscopy Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
 Table 2. Global Hemostatic Agents in Endoscopy Market Size Growth Rate by Product, 2021 vs 2025 vs 2032 (US$ Million)
 Table 3. Global Hemostatic Agents in Endoscopy Market Size Growth Rate by Biodegradability, 2021 vs 2025 vs 2032 (US$ Million)
 Table 4. Global Hemostatic Agents in Endoscopy Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
 Table 5. Global Hemostatic Agents in Endoscopy Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 6. Global Hemostatic Agents in Endoscopy Revenue by Region (US$ Million), 2021-2026
 Table 7. Global Hemostatic Agents in Endoscopy Revenue by Region (US$ Million), 2027-2032
 Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
 Table 9. Global Hemostatic Agents in Endoscopy Revenue by Players (US$ Million), 2021-2026
 Table 10. Global Hemostatic Agents in Endoscopy Revenue-Based Market Share by Players (2021-2026)
 Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
 Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Hemostatic Agents in Endoscopy Revenue, 2025
 Table 13. Global Hemostatic Agents in Endoscopy Average Gross Margin (%) by Player (2021 vs 2025)
 Table 14. Global Hemostatic Agents in Endoscopy Companies Headquarters
 Table 15. Global Hemostatic Agents in Endoscopy Market Concentration Ratio (CR5)
 Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
 Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 18. Global Hemostatic Agents in Endoscopy Revenue by Type (US$ Million), 2021-2026
 Table 19. Global Hemostatic Agents in Endoscopy Revenue by Type (US$ Million), 2027-2032
 Table 20. Global Hemostatic Agents in Endoscopy Revenue by Product (US$ Million), 2021-2026
 Table 21. Global Hemostatic Agents in Endoscopy Revenue by Product (US$ Million), 2027-2032
 Table 22. Global Hemostatic Agents in Endoscopy Revenue by Biodegradability (US$ Million), 2021-2026
 Table 23. Global Hemostatic Agents in Endoscopy Revenue by Biodegradability (US$ Million), 2027-2032
 Table 24. Key Product Attributes and Differentiation
 Table 25. Global Hemostatic Agents in Endoscopy Revenue by Application (US$ Million), 2021-2026
 Table 26. Global Hemostatic Agents in Endoscopy Revenue by Application (US$ Million), 2027-2032
 Table 27. Hemostatic Agents in Endoscopy High-Growth Sectors Demand CAGR (2026-2032)
 Table 28. Top Customers by Region
 Table 29. Top Customers by Application
 Table 30. North America Hemostatic Agents in Endoscopy Growth Accelerators and Market Barriers
 Table 31. North America Hemostatic Agents in Endoscopy Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
 Table 32. Europe Hemostatic Agents in Endoscopy Growth Accelerators and Market Barriers
 Table 33. Europe Hemostatic Agents in Endoscopy Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 34. Asia-Pacific Hemostatic Agents in Endoscopy Growth Accelerators and Market Barriers
 Table 35. Asia-Pacific Hemostatic Agents in Endoscopy Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Central and South America Hemostatic Agents in Endoscopy Investment Opportunities and Key Challenges
 Table 37. Central and South America Hemostatic Agents in Endoscopy Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
 Table 38. Middle East and Africa Hemostatic Agents in Endoscopy Investment Opportunities and Key Challenges
 Table 39. Middle East and Africa Hemostatic Agents in Endoscopy Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
 Table 40. Cook Medical Corporation Information
 Table 41. Cook Medical Description and Major Businesses
 Table 42. Cook Medical Product Features and Attributes
 Table 43. Cook Medical Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 44. Cook Medical Revenue Proportion by Product in 2025
 Table 45. Cook Medical Revenue Proportion by Application in 2025
 Table 46. Cook Medical Revenue Proportion by Geographic Area in 2025
 Table 47. Cook Medical Hemostatic Agents in Endoscopy SWOT Analysis
 Table 48. Cook Medical Recent Developments
 Table 49. 3-D Matrix Corporation Information
 Table 50. 3-D Matrix Description and Major Businesses
 Table 51. 3-D Matrix Product Features and Attributes
 Table 52. 3-D Matrix Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 53. 3-D Matrix Revenue Proportion by Product in 2025
 Table 54. 3-D Matrix Revenue Proportion by Application in 2025
 Table 55. 3-D Matrix Revenue Proportion by Geographic Area in 2025
 Table 56. 3-D Matrix Hemostatic Agents in Endoscopy SWOT Analysis
 Table 57. 3-D Matrix Recent Developments
 Table 58. EndoClot Plus Corporation Information
 Table 59. EndoClot Plus Description and Major Businesses
 Table 60. EndoClot Plus Product Features and Attributes
 Table 61. EndoClot Plus Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 62. EndoClot Plus Revenue Proportion by Product in 2025
 Table 63. EndoClot Plus Revenue Proportion by Application in 2025
 Table 64. EndoClot Plus Revenue Proportion by Geographic Area in 2025
 Table 65. EndoClot Plus Hemostatic Agents in Endoscopy SWOT Analysis
 Table 66. EndoClot Plus Recent Developments
 Table 67. Next Biomedical Corporation Information
 Table 68. Next Biomedical Description and Major Businesses
 Table 69. Next Biomedical Product Features and Attributes
 Table 70. Next Biomedical Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 71. Next Biomedical Revenue Proportion by Product in 2025
 Table 72. Next Biomedical Revenue Proportion by Application in 2025
 Table 73. Next Biomedical Revenue Proportion by Geographic Area in 2025
 Table 74. Next Biomedical Hemostatic Agents in Endoscopy SWOT Analysis
 Table 75. Next Biomedical Recent Developments
 Table 76. BioCer Entwicklungs Corporation Information
 Table 77. BioCer Entwicklungs Description and Major Businesses
 Table 78. BioCer Entwicklungs Product Features and Attributes
 Table 79. BioCer Entwicklungs Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 80. BioCer Entwicklungs Revenue Proportion by Product in 2025
 Table 81. BioCer Entwicklungs Revenue Proportion by Application in 2025
 Table 82. BioCer Entwicklungs Revenue Proportion by Geographic Area in 2025
 Table 83. BioCer Entwicklungs Hemostatic Agents in Endoscopy SWOT Analysis
 Table 84. BioCer Entwicklungs Recent Developments
 Table 85. Technologies, Platforms and Infrastructure
 Table 86. Distributors List
 Table 87. Market Trends and Market Evolution
 Table 88. Market Drivers and Opportunities
 Table 89. Market Challenges, Risks, and Restraints
 Table 90. Research Programs/Design for This Report
 Table 91. Key Data Information from Secondary Sources
 Table 92. Key Data Information from Primary Sources


List of Figures
 Figure 1. Global Hemostatic Agents in Endoscopy Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
 Figure 2. Peptide Hydrogels Product Picture
 Figure 3. Mineral Hemostatic Powder Product Picture
 Figure 4. Other Product Picture
 Figure 5. Global Hemostatic Agents in Endoscopy Market Size Growth Rate by Product, 2021 vs 2025 vs 2032 (US$ Million)
 Figure 6. Self-assembling Type Product Picture
 Figure 7. Spray Type Product Picture
 Figure 8. Other Product Picture
 Figure 9. Global Hemostatic Agents in Endoscopy Market Size Growth Rate by Biodegradability, 2021 vs 2025 vs 2032 (US$ Million)
 Figure 10. Absorbable / Biodegradable Agents Product Picture
 Figure 11. Temporary Non-Absorptive Barrier Systems Product Picture
 Figure 12. Global Hemostatic Agents in Endoscopy Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
 Figure 13. ESD
 Figure 14. EMR
 Figure 15. Other
 Figure 16. Hemostatic Agents in Endoscopy Report Years Considered
 Figure 17. Global Hemostatic Agents in Endoscopy Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 18. Global Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 19. Global Hemostatic Agents in Endoscopy Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Figure 20. Global Hemostatic Agents in Endoscopy Revenue-Based Market Share by Region (2021-2032)
 Figure 21. Global Hemostatic Agents in Endoscopy Revenue-Based Market Share Ranking (2025)
 Figure 22. Tier Distribution by Revenue Contribution (2021 vs 2025)
 Figure 23. Peptide Hydrogels Revenue-Based Market Share by Player in 2025
 Figure 24. Mineral Hemostatic Powder Revenue-Based Market Share by Player in 2025
 Figure 25. Other Revenue-Based Market Share by Player in 2025
 Figure 26. Global Hemostatic Agents in Endoscopy Revenue-Based Market Share by Type (2021-2032)
 Figure 27. Global Hemostatic Agents in Endoscopy Revenue-Based Market Share by Product (2021-2032)
 Figure 28. Global Hemostatic Agents in Endoscopy Revenue-Based Market Share by Biodegradability (2021-2032)
 Figure 29. Global Hemostatic Agents in Endoscopy Revenue-Based Market Share by Application (2021-2032)
 Figure 30. North America Hemostatic Agents in Endoscopy Revenue YoY (US$ Million), 2021-2032
 Figure 31. North America Top 5 Players Hemostatic Agents in Endoscopy Revenue (US$ Million) in 2025
 Figure 32. North America Hemostatic Agents in Endoscopy Revenue (US$ Million) by Application (2021-2032)
 Figure 33. US Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 34. Canada Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 35. Mexico Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 36. Europe Hemostatic Agents in Endoscopy Revenue YoY (US$ Million), 2021-2032
 Figure 37. Europe Top 5 Players Hemostatic Agents in Endoscopy Revenue (US$ Million) in 2025
 Figure 38. Europe Hemostatic Agents in Endoscopy Revenue (US$ Million) by Application (2021-2032)
 Figure 39. Germany Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 40. France Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 41. U.K. Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 42. Italy Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 43. Russia Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 44. Asia-Pacific Hemostatic Agents in Endoscopy Revenue YoY (US$ Million), 2021-2032
 Figure 45. Asia-Pacific Top 8 Players Hemostatic Agents in Endoscopy Revenue (US$ Million) in 2025
 Figure 46. Asia-Pacific Hemostatic Agents in Endoscopy Revenue (US$ Million) by Application (2021-2032)
 Figure 47. Indonesia Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 48. Japan Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 49. South Korea Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 50. Australia Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 51. India Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 52. Indonesia Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 53. Vietnam Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 54. Malaysia Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 55. Philippines Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 56. Singapore Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 57. Central and South America Hemostatic Agents in Endoscopy Revenue YoY (US$ Million), 2021-2032
 Figure 58. Central and South America Top 5 Players Hemostatic Agents in Endoscopy Revenue (US$ Million) in 2025
 Figure 59. Central and South America Hemostatic Agents in Endoscopy Revenue (US$ Million) by Application (2021-2032)
 Figure 60. Brazil Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 61. Argentina Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 62. Middle East and Africa Hemostatic Agents in Endoscopy Revenue YoY (US$ Million), 2021-2032
 Figure 63. Middle East and Africa Top 5 Players Hemostatic Agents in Endoscopy Revenue (US$ Million) in 2025
 Figure 64. Middle East and Africa Hemostatic Agents in Endoscopy Revenue (US$ Million) by Application (2021-2032)
 Figure 65. GCC Countries Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 66. Israel Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 67. Egypt Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 68. South Africa Hemostatic Agents in Endoscopy Revenue (US$ Million), 2021-2032
 Figure 69. Hemostatic Agents in Endoscopy Value Chain Mapping
 Figure 70. Channels of Distribution (Direct Vs Distribution)
 Figure 71. Bottom-up and Top-down Approaches for This Report
 Figure 72. Data Triangulation
 Figure 73. Key Executives Interviewed

本レポートが解明する主要な課題

2032年、世界の内視鏡用止血剤市場規模はいくらですか？
2032年、世界の内視鏡用止血剤市場規模は364です。
2026年から2032年までの世界の内視鏡用止血剤市場規模の年間複合成長率（CAGR）はどのくらいですか？
2026年から2032年までの世界の内視鏡用止血剤市場規模の年間複合成長率（CAGR）は12.4%です。
どの地域が最も高い市場シェアを占めることが予想されていますか？
各地域市場について、市場規模、年間複合成長率（CAGR）、市場需要、産業構造、政策環境、主要企業の展開状況など多角的な観点から詳細な比較分析を行い、各地域の市場特性と競争環境を体系的に整理しました。また、各地域の需要構造、市場成長の原動力、投資環境についても重点的に分析し、企業が重点地域市場を特定したり、グローバル市場戦略や販売戦略を策定する上で貴重な参考情報を提供します。
2026年、世界の内視鏡用止血剤市場規模はいくらですか？
2026年、世界の内視鏡用止血剤市場規模は181です。